Pacific Biosciences Of California (PACB) Net Cash Flow (2010 - 2026)

Pacific Biosciences Of California's Net Cash Flow history runs 17 years deep, the most recent figure standing at -$7.4 million for Q1 2026.

• On a quarterly basis, Net Cash Flow fell 335.73% year-over-year to -$7.4 million in Q1 2026; TTM through Mar 2026 was -$2.9 million, a 84.63% increase from a year earlier, with the FY2025 full-year figure at $7.7 million, up 106.13% from the prior year.
• Net Cash Flow slipped to -$7.4 million in Q1 2026 per PACB's latest filing, from $7.0 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $176.4 million in Q3 2023 and bottomed at -$205.7 million in Q4 2023.
• The 5-year median for Net Cash Flow is -$6.0 million (2022), against an average of -$24.0 million.
• Biggest YoY gain for Net Cash Flow was 3033.48% in 2023; the steepest drop was 1096.02% in 2023.
• Year by year, Net Cash Flow stood at $20.7 million in 2022, then slumped by 1096.02% to -$205.7 million in 2023, then surged by 89.01% to -$22.6 million in 2024, then soared by 130.78% to $7.0 million in 2025, then tumbled by 206.25% to -$7.4 million in 2026.
• Per Business Quant, the three latest PACB Net Cash Flow figures stand at -$7.4 million (Q1 2026), $7.0 million (Q4 2025), and $1.7 million (Q3 2025).